Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.
Adjuvant formulations capable of inducing high titer and high affinity antibody responses would provide a major advance in the development of vaccines to viral infections such as HIV-1. Although oil-in-water emulsions, such as Freund's adjuvant (FCA/FIA), are known to be potent, their toxicity...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3324409?pdf=render |
| _version_ | 1819089343417942016 |
|---|---|
| author | Rachel P J Lai Michael S Seaman Paul Tonks Frank Wegmann David J Seilly Simon D W Frost Celia C LaBranche David C Montefiori Antu K Dey Indresh K Srivastava Quentin Sattentau Susan W Barnett Jonathan L Heeney |
| author_facet | Rachel P J Lai Michael S Seaman Paul Tonks Frank Wegmann David J Seilly Simon D W Frost Celia C LaBranche David C Montefiori Antu K Dey Indresh K Srivastava Quentin Sattentau Susan W Barnett Jonathan L Heeney |
| author_sort | Rachel P J Lai |
| collection | DOAJ |
| description | Adjuvant formulations capable of inducing high titer and high affinity antibody responses would provide a major advance in the development of vaccines to viral infections such as HIV-1. Although oil-in-water emulsions, such as Freund's adjuvant (FCA/FIA), are known to be potent, their toxicity and reactogenicity make them unacceptable for human use. Here, we explored different adjuvants and compared their ability to elicit antibody responses to FCA/FIA. Recombinant soluble trimeric HIV-1 gp140 antigen was formulated in different adjuvants, including FCA/FIA, Carbopol-971P, Carbopol-974P and the licensed adjuvant MF59, or combinations of MF59 and Carbopol. The antigen-adjuvant formulation was administered in a prime-boost regimen into rabbits, and elicitation of antigen binding and neutralizing antibodies (nAbs) was evaluated. When used individually, only FCA/FIA elicited significantly higher titer of nAbs than the control group (gp140 in PBS (p<0.05)). Sequential prime-boost immunizations with different adjuvants did not offer improvements over the use of FCA/FIA or MF59. Remarkably however, the concurrent use of the combination of Carbopol-971P and MF59 induced potent adjuvant activity with significantly higher titer nAbs than FCA/FIA (p<0.05). This combination was not associated with any obvious local or systemic adverse effects. Antibody competition indicated that the majority of the neutralizing activities were directed to the CD4 binding site (CD4bs). Increased antibody titers to the gp41 membrane proximal external region (MPER) and gp120 V3 were detected when the more potent adjuvants were used. These data reveal that the combination of Carbopol-971P and MF59 is unusually potent for eliciting nAbs to a variety of HIV-1 nAb epitopes. |
| first_indexed | 2024-12-21T22:06:26Z |
| format | Article |
| id | doaj.art-b6164ba779f540a7a686c48121fcaab3 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T22:06:26Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-b6164ba779f540a7a686c48121fcaab32022-12-21T18:48:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0174e3508310.1371/journal.pone.0035083Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.Rachel P J LaiMichael S SeamanPaul TonksFrank WegmannDavid J SeillySimon D W FrostCelia C LaBrancheDavid C MontefioriAntu K DeyIndresh K SrivastavaQuentin SattentauSusan W BarnettJonathan L HeeneyAdjuvant formulations capable of inducing high titer and high affinity antibody responses would provide a major advance in the development of vaccines to viral infections such as HIV-1. Although oil-in-water emulsions, such as Freund's adjuvant (FCA/FIA), are known to be potent, their toxicity and reactogenicity make them unacceptable for human use. Here, we explored different adjuvants and compared their ability to elicit antibody responses to FCA/FIA. Recombinant soluble trimeric HIV-1 gp140 antigen was formulated in different adjuvants, including FCA/FIA, Carbopol-971P, Carbopol-974P and the licensed adjuvant MF59, or combinations of MF59 and Carbopol. The antigen-adjuvant formulation was administered in a prime-boost regimen into rabbits, and elicitation of antigen binding and neutralizing antibodies (nAbs) was evaluated. When used individually, only FCA/FIA elicited significantly higher titer of nAbs than the control group (gp140 in PBS (p<0.05)). Sequential prime-boost immunizations with different adjuvants did not offer improvements over the use of FCA/FIA or MF59. Remarkably however, the concurrent use of the combination of Carbopol-971P and MF59 induced potent adjuvant activity with significantly higher titer nAbs than FCA/FIA (p<0.05). This combination was not associated with any obvious local or systemic adverse effects. Antibody competition indicated that the majority of the neutralizing activities were directed to the CD4 binding site (CD4bs). Increased antibody titers to the gp41 membrane proximal external region (MPER) and gp120 V3 were detected when the more potent adjuvants were used. These data reveal that the combination of Carbopol-971P and MF59 is unusually potent for eliciting nAbs to a variety of HIV-1 nAb epitopes.http://europepmc.org/articles/PMC3324409?pdf=render |
| spellingShingle | Rachel P J Lai Michael S Seaman Paul Tonks Frank Wegmann David J Seilly Simon D W Frost Celia C LaBranche David C Montefiori Antu K Dey Indresh K Srivastava Quentin Sattentau Susan W Barnett Jonathan L Heeney Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. PLoS ONE |
| title | Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. |
| title_full | Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. |
| title_fullStr | Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. |
| title_full_unstemmed | Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. |
| title_short | Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. |
| title_sort | mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to freund s adjuvants |
| url | http://europepmc.org/articles/PMC3324409?pdf=render |
| work_keys_str_mv | AT rachelpjlai mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants AT michaelsseaman mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants AT paultonks mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants AT frankwegmann mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants AT davidjseilly mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants AT simondwfrost mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants AT celiaclabranche mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants AT davidcmontefiori mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants AT antukdey mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants AT indreshksrivastava mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants AT quentinsattentau mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants AT susanwbarnett mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants AT jonathanlheeney mixedadjuvantformulationsrevealanewcombinationthatelicitantibodyresponsecomparabletofreundsadjuvants |